Palliative Radiation Therapy — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

Palliative radiation therapy (palliative radiotherapy) is the use of ionising radiation to relieve symptoms caused by cancer — most commonly pain, bleeding, airway or oesophageal obstruction, and neurological compromise from brain or spinal cord metastases — rather than to cure the underlying malignancy. It is a cornerstone of oncological palliative care, providing effective symptom relief with minimal impact on the patient's daily function and quality of life. Approximately 50% of all cancer patients receive radiotherapy at some point in their illness, and a substantial proportion of these treatments are given with palliative intent. The underlying mechanism is the same as curative radiotherapy: ionising radiation (high-energy X-rays, or less commonly electrons or protons) causes DNA double-strand breaks in cancer cells, leading to cell death. In palliative treatment, the goal is to reduce tumour volume sufficiently to relieve pressure, obstruction, or invasion of surrounding structures — not to eradicate every cancer cell. Palliative radiotherapy regimens are therefore generally shorter and use fewer fractions (treatments) than curative courses: common schedules range from a single fraction (8 Gy in one session for bone pain) to 5 fractions over one week, 10 fractions over 2 weeks, or 20 fractions over 4 weeks for more complex targets. Modern radiotherapy delivery uses linear accelerators (LINACs) with CT-based planning, multi-leaf collimators, and IMRT/VMAT techniques to shape the radiation dose to the target volume, minimising dose to surrounding healthy tissues even in the palliative setting.

Palliative radiotherapy is indicated for any patient with advanced or metastatic cancer experiencing symptoms attributable to a localised tumour deposit that can be targeted with an acceptable radiation dose and expected benefit that outweighs the treatment burden. Bone metastases causing pain: the most common indication for palliative radiotherapy. Approximately 80% of patients with painful bone metastases (from breast, prostate, lung, kidney, thyroid cancers) achieve meaningful pain relief with a single 8 Gy fraction — the ASTRO, ESTRO, and NICE guidelines all support single-fraction treatment as equivalent to multi-fraction schedules for uncomplicated bone pain. Metastatic spinal cord compression (MSCC): urgent radiotherapy (or surgical decompression followed by radiotherapy) is the standard treatment for MSCC — patients must be identified before complete neurological loss, as outcome is directly related to neurological function at the time treatment begins; urgent same-day referral is essential. Brain metastases: whole brain radiotherapy (WBRT) or stereotactic radiosurgery (SRS) is used for symptomatic brain metastases causing headache, neurological deficit, or seizures. Haemorrhage control: palliative radiotherapy effectively controls bleeding from locally advanced rectal cancer, bladder cancer, cervical cancer, or lung cancer. Airway or oesophageal obstruction: external beam radiotherapy reduces tumour bulk causing dysphagia, dyspnoea, or superior vena cava obstruction. Soft tissue fungating wounds: palliative radiotherapy reduces tumour size, reduces bleeding, and can significantly improve the management of ulcerating cancer deposits. Patient performance status, life expectancy (generally at least 1–3 months for most palliative courses), and logistical ability to attend radiotherapy are considered in treatment selection.

Palliative radiotherapy is delivered in the radiotherapy department of a cancer centre using a linear accelerator. The treatment planning process for palliative radiotherapy is streamlined compared to curative courses, reflecting the need for rapid delivery when patients are symptomatic. For straightforward bone metastases: a CT planning scan in the treatment position allows the radiation oncologist to define the target (the painful metastasis and surrounding bone) and organs at risk (spinal cord, kidneys, bowel). A simple two-field or three-field treatment plan is generated; a single 8 Gy fraction can typically be planned and treated within 24–48 hours of referral at most centres. For spinal cord compression and brain metastases: treatment planning is more detailed, involving MRI fusion with the CT planning scan to accurately delineate the spinal cord or brain metastases, and more complex field arrangements to spare the spinal cord while delivering adequate dose to vertebral metastases. For each treatment session: the patient lies on the treatment couch in the same reproducible position (confirmed by immobilisation devices — thermoplastic shells for head/neck/brain, vacuum moulds for body), and lasers align the patient to set-up marks (skin tattoos) placed at the planning CT. The LINAC is then operated from outside the room; the treatment gantry rotates around the patient delivering the prescribed dose. The radiation beam itself is invisible and painless. Each treatment session takes 10–20 minutes in total (including setup time); the beam-on time is typically 2–5 minutes. Patients drive themselves home or have a relative collect them — no sedation is required.

Palliative radiotherapy provides rapid and effective symptom relief for the majority of patients. Bone pain: the most robust evidence base in palliative oncology. Meta-analyses including over 25 randomised trials show that overall pain response (complete or partial) occurs in approximately 60–70% of patients treated for painful bone metastases; complete pain relief is achieved in 25–30%. The onset of pain relief typically begins 7–14 days after irradiation and continues to develop for 4–6 weeks. A single 8 Gy fraction is equivalent to multi-fraction schedules in efficacy for uncomplicated bone pain (ASTRO guidelines 2017) and significantly more convenient. Spinal cord compression: urgent radiotherapy within 24 hours of symptom onset preserves or restores neurological function in 70–80% of patients who are ambulatory at treatment — outcomes are markedly worse when patients are paraplegic at presentation (20–30% regain ambulation). Haemorrhage control: palliative radiotherapy achieves haemostasis in 80–90% of patients with bleeding from rectum, bladder, or cervix, typically within 2–4 weeks. Brain metastases: SRS (stereotactic radiosurgery) achieves local control of treated lesions in 85–90% of patients at 1 year; WBRT controls neurological symptoms in approximately 75% of patients. Quality-of-life preservation is a central goal: palliative radiotherapy is specifically designed to achieve its effects with a minimal side effect burden, allowing patients to maintain function and remain at home during and after treatment.

Palliative radiotherapy side effects are site-specific and generally less severe than curative courses because lower total doses are delivered over fewer fractions. Radiation to bone metastases: a pain flare — temporary worsening of bone pain in the first 2–3 days after a single fraction — occurs in approximately 40% of patients; pre-treatment dexamethasone and analgesic cover minimise this. Radiation to the spine: acute effects include local skin erythema and fatigue; nausea occurs with lower thoracic/lumbar field; bowel cramping with lower lumbar/sacral field. Oesophagitis (difficulty swallowing) occurs with thoracic spine radiotherapy. Radiation to the brain (WBRT): acute effects include headache (managed with dexamethasone), fatigue, scalp erythema, and temporary hair loss (alopecia) within the radiation field — hair may re-grow partially after lower-dose palliative courses. Cognitive side effects from WBRT are a significant concern — short-term memory and concentration are affected in a proportion of patients receiving WBRT; neuroprotective agents (memantine) and hippocampal-avoidance WBRT reduce this risk. Radiation to the pelvis: diarrhoea, urinary frequency, and fatigue; mucositis with rectal involvement. Radiation to the chest: oesophagitis, dry cough, and fatigue. Most acute side effects resolve within 2–4 weeks of completing treatment. Late effects (occurring months to years later) are less clinically relevant in most palliative patients given prognosis, but are still considered in treatment planning to protect the spinal cord and other critical structures.

Recovery from palliative radiotherapy is generally rapid and well-tolerated compared to other anti-cancer treatments. After a single-fraction bone treatment: patients may drive home the same day. Fatigue is common for 1–2 weeks. The pain flare (if it occurs) peaks at days 2–5 and is managed with regular analgesics and a short course of dexamethasone (4 mg twice daily for 3 days). Pain relief typically becomes apparent within 7–14 days and continues to improve for 4–6 weeks. Analgesic dose should be titrated as pain improves to avoid over-sedation from medications that are no longer needed at the same dose. After multi-fraction treatments (5–20 fractions): site-specific side effects as described above; most resolve within 2–4 weeks of the final fraction. Skin care: the treated skin should be washed gently with mild soap and water; avoid sun exposure, tight clothing, and heat (hot water bottles, electric blankets) to the treated area during treatment and for 4–8 weeks after completion. Fatigue management: pacing, maintaining a gentle activity routine (short walks), and adequate nutrition support functional recovery. Follow-up: the oncology team reviews response at 4–6 weeks, assessing symptom response, toxicity, and whether further anti-cancer treatment or a repeat course of radiotherapy is appropriate. Re-irradiation to previously treated sites is sometimes possible for recurrent pain and is considered based on prior dose to critical structures.